The estimated Net Worth of John Pratt is at least $24.4 Тысяча dollars as of 12 June 2013. John Pratt owns over 21,032 units of Pacira BioSciences Inc stock worth over $24,375 and over the last 13 years John sold PCRX stock worth over $0.
John has made over 3 trades of the Pacira BioSciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently John exercised 21,032 units of PCRX stock worth $223,360 on 12 June 2013.
The largest trade John's ever made was exercising 21,032 units of Pacira BioSciences Inc stock on 12 June 2013 worth over $223,360. On average, John trades about 9,750 units every 18 days since 2012. As of 12 June 2013 John still owns at least 1,875 units of Pacira BioSciences Inc stock.
You can see the complete history of John Pratt stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O PACIRA PHARMACEUTICALS, INC., 10450 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon и Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: